{"entity":{"id":"nct05838729","kind":"trial","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","aka":[],"tldr":"A phase 1/2 trial of RiMO-301 in advanced solid tumours, run by Coordination Pharmaceuticals, Inc., now recruiting.","summary":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer is a phase 1/2 interventional study registered as NCT05838729 by Coordination Pharmaceuticals, Inc., with 16 participants planned, started 2023-04-03 and due to reach its primary completion in 2026-09. Interventions recorded: RiMO-301.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05838729","url":"https://clinicaltrials.gov/study/NCT05838729"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05838729","phase":"1/2","setting":"Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer","sponsor":"Coordination Pharmaceuticals, Inc.","enrolled":16,"outcomes":[]},"route":"/trials/nct05838729/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}